Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 2 (1)

Trial Status

Active Not Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT04200443Phase 2Active Not Recruiting

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

NCT02601209Phase 1Terminated

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Showing all 2 trials

Research Network

Activity Timeline